Creo Medical Group PLC (AIM:CREO)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 61.76M +9.6% |
| Revenue (ttm) | 6.00M +50.0% |
| Net Income | 5.30M |
| EPS | 0.01 |
| Shares Out | 449.14M |
| PE Ratio | 11.65 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 174,002 |
| Open | 13.65 |
| Previous Close | 13.63 |
| Day's Range | 13.50 - 14.00 |
| 52-Week Range | 9.52 - 18.50 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 55.00 (+306.5%) |
| Earnings Date | Sep 11, 2026 |
About Creo Medical Group
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. It also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for CREO stock is "Strong Buy" and the 12-month stock price target is 55p.
News
Creo Medical Group sees 50% surge in year-on-year revenues
Creo Medical Group reported revenues of £6mn for 2025, up 50% year-on-year, while second-half sales growth accelerated to 58%.